What is the difference between GLP-2 and LL-37?

GLP-2: Binds GLP-2 receptor on intestinal enteroendocrine cells. Promotes enterocyte proliferation and reduces apoptosis, increasing villus height and crypt depth. LL-37: Human cathelicidin antimicrobial peptide; disrupts bacterial membranes and modulates innate immune response via TLR signaling

Is GLP-2 FDA approved?

GLP-2 is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is GLP-2 administered in research settings?

In research settings, GLP-2 is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

How is LL-37 administered in research settings?

In research settings, LL-37 is typically administered via the subcutaneous, topical, or intravenous routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›GLP-2 vs LL-37

Peptide Comparison

GLP-2 vs LL-37

Name: GLP-2 vs LL-37 — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Tissue Repair peptides.

GLP-2

Glucagon-like Peptide-2

RecoveryNot EvaluatedResearch Only

13 providers listed

Full GLP-2 profile →

LL-37

cathelicidin

RecoveryResearch Only

Half-life: ~30 minutes

51 providers listed

Full LL-37 profile →

Bottom line

GLP-2 carries stronger published evidence (RCT, 7 key studies) than LL-37 (Cohort study, 6); both are research compounds.

Quick Verdict

GLP-2

Half-life

—

LL-37

Half-life

~30 minutes

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	GLP-2
More provider options (13 vs 51)	LL-37

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

GLP-2

LL-37

Mechanism Family

Tissue Repair

Half-life

—

~30 minutes

FDA Status

not evaluated

nomination withdrawn

Admin Routes

subcutaneous

subcutaneous, topical, intravenous

Availability

Research Only

Providers

13 listed

51 listed

Avail. Notes

Native GLP-2 is not an FDA-approved drug substance; an openFDA ingredient search for "glucagon-like" returns no approved product. The approved product is teduglutide (Gattex, NDA 203441, original approval 2012-12-21), a 33-amino-acid ANALOG of human GLP-2 — see the separate teduglutide profile. The 2012-08-30 date previously carried on this record corresponds to no locatable FDA approval action and has been removed.

Human cathelicidin antimicrobial peptide. Phase 1/2 trials for wound healing. No FDA approval, no NDA. Early investigational stage only. Not commercially available in US.

Research Evidence

GLP-2

RCT · 7 key studies · most recent 2026

LL-37

Cohort study · 6 key studies · most recent 2026

Research Citations

GLP-2

RCT2018 · Nutrition in Clinical Practice

Reduction of Parenteral Nutrition and Hydration Support and Safety With Long-Term Teduglutide Treatment in Pa…

Case series2026 · JPGN Rep

PERCC1-associated enteropathy: Diagnostic challenges and enteral autonomy achieved with teduglutide.

Cohort2026 · Clin Nutr

From childhood to adulthood in chronic intestinal failure: A nationwide study.

Cohort2026 · Clin Nutr

Impact of intestinal resections on the secretion of gastrointestinal hormones.

+3 more

LL-37

Cohort2026 · Children (Basel)

The Role of Vitamin D in Modulating the Innate Immune Response in Children with Vesicoureteral Reflux.

In vitro2026 · Front Immunol

Immunomodulatory effects of synthetic antimicrobial peptides on LPS-induced inflammatory responses in THP-1 m…

Animal2026 · bioRxiv

A protease-sensing circuit links neutrophil inflammation to virulence regulation in Streptococcus pyogenes.

Animal2026 · Sci Adv

Serine protease HtrA promotes Campylobacter jejuni intestinal colonization through degrading antimicrobial pe…

+2 more

About GLP-2

Binds GLP-2 receptor on intestinal enteroendocrine cells. Promotes enterocyte proliferation and reduces apoptosis, increasing villus height and crypt depth. Strengthens tight junctions and reduces intestinal permeability.

Research Areas

gut lining repairintestinal integritybarrier functionanti-inflammatory

About LL-37

Human cathelicidin antimicrobial peptide; disrupts bacterial membranes and modulates innate immune response via TLR signaling

Research Areas

antimicrobialimmune modulationwound healinganti-biofilm

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

GLP-2

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Suggested Monitoring

Under clinical review

Being verified by our medical team before we display monitoring guidance for this peptide.

LL-37

Reported (Unverified — Pending Clinical Review)

sepsis risk (may be pro-inflammatory at high doses)

No established clinical contraindications

Price (per mg)

GLP-2

$8.33/mg

$5.99 – $11.16 range

8 vendors

View price index →Find providers →

LL-37

$9.66/mg

$7.80 – $15.20 range

36 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

GLP-2

13 listed

Browse directory →

Providers offering

LL-37

51 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Tissue Repair Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated October 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). GLP-2 vs LL-37 — Per-mg Price Comparison. Retrieved October 27, 2026, from https://peptidebase.io/peptides/compare/glp-2/ll-37

https://peptidebase.io/peptides/compare/glp-2/ll-37 Methodology License Download JSON Download CSV